Etcembly Ltd’s Post

⚠ Don't miss your chance! Free webcast series starting next week! 6 FREE Webcasts: Antibody Engineering & Therapeutics Spring Digital Week taking place May 20 - 21, 2024 | Join hundreds of your antibody peers 👉 Find out more & secure your free pass here: https://lnkd.in/esk6vcix Design Meets Biology – Engineering Immune Engagers with Potentially Improved Therapeutic Index 🕘 May 21: 10am EDT / 3pm BST / 4pm CEST Current efforts in T cell engagers primarily rely upon the engagement and activation of CD3, leading to systemic activation of T cells, elevated cytokine release, and poor therapeutic index limited by toxicity. Toward improving therapeutic index and limiting pan T cell activation, we aim to selectively expand and activate virus-specific CD8+ effector memory T cells that are resident in the tumor microenvironment via DuetMab-guided pMHC staging (GPS) molecules. 👥 Speaker: John Schardt, Senior Scientist, AstraZeneca #AntibodyEngineering #Therapeutics #AntibodyDiscovery #AcceleratedDiscovery #TherapeuticIndex

6 FREE Webcasts: Antibody Engineering & Therapeutics Spring Digital Week taking place May 20 - 21, 2024 | Join hundreds of your antibody peers 👉 Find out more & secure your free pass here: https://lnkd.in/e3nbaWkG Design Meets Biology – Engineering Immune Engagers with Potentially Improved Therapeutic Index 🕘 May 21: 10am EDT / 3pm BST / 4pm CEST Current efforts in T cell engagers primarily rely upon the engagement and activation of CD3, leading to systemic activation of T cells, elevated cytokine release, and poor therapeutic index limited by toxicity. Toward improving therapeutic index and limiting pan T cell activation, we aim to selectively expand and activate virus-specific CD8+ effector memory T cells that are resident in the tumor microenvironment via DuetMab-guided pMHC staging (GPS) molecules. 👥 Speaker: John Schardt, Senior Scientist, AstraZeneca #AntibodyEngineering #Therapeutics #AntibodyDiscovery #AcceleratedDiscovery #TherapeuticIndex

💊Exciting News! 💊 From June 20-21, Lionel Renaud, Senior Modeler at LYO-X, will be attending the 12th Antibody Industrial Symposium (AIS2024) in picturesque Montpellier, France! This prestigious conference brings together experts in therapeutic antibodies, recombinant proteins, and cellular immunotherapy to share the latest in research, development, and clinical advancements. We're thrilled to announce that Lionel, invited by Pierre Ferre, SVP of Preclinical Development & Corporate Operations at Compugen, will be delivering an insightful talk. He will discuss how PK/PD modeling can be a game-changer in overcoming challenges and avoiding pitfalls in therapeutic antibody development. In his presentation, Lionel will delve into:  🎯 Tackling reduced antibody exposure due to target-mediated drug disposition (TMDD)  📊 Understanding factors influencing effect duration (target turnover, antibody-target binding affinity)  ⛵ Navigating target cross-reactivity  😷 Addressing antibody immunogenicity in preclinical species Don't miss this opportunity to gain valuable insights from Lionel's expertise. Date: 21 June 2024 Time: 08:30hrs Venue: CORUM Conference Centre, Montpellier (F), Einstein Auditorium Stay tuned for updates from AIS2024! #AIS2024 #AntibodyTherapeutics #PKPDModeling #LYOX #Compugen #TherapeuticAntibodies #Immunotherapy #BiotechInnovation

🚀 Join Us for a Game-Changing Event in Therapeutic Antibody Development! 🚀 📅 Dates: October 28 & 29, 2024 🕒 Time: 11:30 AM ET (New York) Conventional preclinical models often fall short in evaluating antibody-based therapeutics. JAX’s cutting-edge humanized models are here to change that! These models faithfully reproduce human physiology and pathology, enabling more accurate predictions of biologic drug candidate performance. 🌟 Why Attend? - Discover how JAX’s humanized models can revolutionize your antibody-based therapeutic development. - Learn from industry experts about the latest trends and innovations. - Engage in insightful presentations and discussions. 🔗 Register Now:  https://lnkd.in/gdaAWkqF Agenda & Speakers: Day 1: Ralph Gareus, Ph.D. - Opening Remarks Silvia Crescioli, Ph.D. - Therapeutic Antibody Formats Dan Rohrer, Ph.D. - Atlas™ Mice Adriano Flora, Ph.D. - HuPK™ Platform Kristin Hovden Aaen, Ph.D. - Human Albumin Fusion Proteins Day 2: Ralph Gareus, Ph.D. - Opening Remarks Brian Soper, Ph.D. - Immune System Humanized Models Samuel Gebhardt - T-Cell Bispecific Antibody Therapy Jiwon Yang, Ph.D., MBA - Safety of Immunotherapies Don’t miss this opportunity to stay ahead in the field of therapeutic antibody development. See you there! #TherapeuticAntibodies #PreclinicalDevelopment #HumanizedModels #TheJacksonLaboratory #Biotech #Pharma #VirtualEvent

🚨 New report alert! We've analyzed data from our online partnering platform, surfacing the latest antibody therapy R&D trends and breakthrough innovations. Highlights include: 📊 Trends in antibody therapy R&D engagement 🧪 Insights from recent industry search campaigns ✨ High-impact antibody therapies seeking partnerships Get your free copy here: https://lnkd.in/e6ZwJN4H #antibodies #antibodytherapies #openinnovation #researchtrends

🔬 Diagonal Therapeutics Raises $128M Series A for Revolutionary 'Activator' Antibody Platform TL;DR: • Cambridge-based biotech developing novel agonist antibodies • Initial focus: HHT and PAH treatments • Backed by Atlas, Lightspeed, BVF Partners, RA Capital, Viking Global • Led by industry veteran Alex Lugovskoy Diagonal Therapeutics is revolutionizing antibody development by focusing on activation rather than inhibition of cellular pathways. Their proprietary computational platform accelerates the discovery of effective agonist antibodies - addressing a critical gap in current therapeutic approaches. Key Programs: ▪️ Hereditary Hemorrhagic Telangiectasia (HHT) - Targeting 150,000+ patients in US/Europe - First-in-class treatment addressing root cause ▪️ Pulmonary Arterial Hypertension (PAH) - Complementary approach to existing treatments - Novel pathway reactivation strategy The funding will advance both programs into early clinical testing, potentially offering new hope for patients with limited treatment options. 💡 Industry Impact: This breakthrough could transform how we approach antibody therapeutics, shifting focus from blocking to activating crucial biological pathways. What are your thoughts on the future of agonist antibodies in rare disease treatment? Share your insights below. #Biotech #DrugDiscovery #RareDiseases #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

Recombinant Antibody Engineering Techniques and Strategies: Dive into the cutting-edge world of recombinant antibody engineering, from optimizing your antibody plasmid, to antibody maturation and humanization. You’ll discover important insights for expediting your antibody engineering projects. We explore innovative techniques and strategies that enhance antibody efficacy, paving the way for breakthroughs in therapeutic development. Learn about: * The importance of optimizing your antibody plasmid construct design * Techniques and considerations for antibody affinity maturation * The process and significance of antibody humanization * And more Request Free!

🎯 Precision antibodies, maximum specificity. PrecisemAb Biotech Co., Ltd. is attending #BIO2024 in San Diego! Visit our booth to learn about our Antibody Lock platform. 🔒 🔒 🔒 ✨ Contact us in the BIO one-on-one partnering system!!We look forward to seeing you!! 🔎 Our Antibody Lock platform enables monoclonal antibodies, ADCs, and bispecific antibodies to selectively target diseased areas, addressing concerns regarding systemic toxicity and enhancing the safety and efficacy of antibody treatments. 🔎 We specialize in developing antibodies targeting various cancer targets and are open to collaborations to apply our Antibody Lock technology to existing antibodies, achieving enhanced efficacy while minimizing side effects, and facilitating faster and more effective drug application in the human body. Yun-Chi Lu #PrecisemAb #Collaboration #AntibodyLock #PrecisionMedicine #MedicalAdvancement #HealthCareInnovation #Lifescience #Pharma #Biotech #OneOnOnePartnering

As therapeutic antibodies continue to unlock new avenues for healing and improving patient outcomes. A quick breezer on • What therapeutic antibodies are • Recent milestones and advancements in therapeutic antibody discovery, development and manufacturing • The future potential of therapeutic antibodies

🌟 Exciting Collaboration Announcement! 🌟 Moderna has entered into a groundbreaking partnership with Leveragen to advance single-domain antibody discovery. Leveragen, renowned for its innovative genetic models, will leverage its proprietary fully human single-domain antibody discovery platform to develop optimized binding modules targeting therapeutic candidates selected by Moderna. 🧬 Under this multi-target research, option, and license agreement, Leveragen will spearhead the discovery of single-domain antibody sequences, while Moderna retains the option to further develop and commercialize the resulting therapies. This collaboration holds immense potential for creating novel mRNA therapeutics to address unmet medical needs. 💡 Leveragen’s founder and CEO, Weisheng Chen, highlighted the advantages of their Singularity Sapiens Mouse platform, which overcomes limitations of conventional transgenic technologies by offering a complete human VH repertoire and robust immune responses. This advanced platform is poised to revolutionize single-domain antibody discovery and development. 📈 Leveragen will receive an undisclosed upfront payment, research funding, and potential milestone payments, along with tiered royalties on global sales. This partnership follows Leveragen’s recent agreement with 92Bio, showcasing the versatility and potential of their cutting-edge technology. Together, Moderna and Leveragen are set to push the boundaries of therapeutic innovation and bring new hope to patients worldwide. #Moderna #Leveragen #AntibodyDiscovery #Biotech #PharmaInnovation #mRNA #Therapeutics #Healthcare